Breaking News

Quintiles Unveils New Predictive and Advanced Analytics Capabilities

June 16, 2015

Provides identification of potential patient safety issues and actionable insight into clinical trial site performance

Quintiles recently added advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and advanced analytics enable study teams to identify the right signals and predict clinical trial site performance and potential patient safety issues.

Predictive and advanced analytics are the first such model-based capabilities fully integrated into an RBM solution on the market today, according to the company. These new capabilities improve precision in risk identification by better understanding underlying “white noise” from safety trigger processes.

“The ultimate goal of risk-based monitoring is to increase the efficiency of drug development while improving quality and patient safety,” said Margaret Keegan, senior vice president, data sciences and strategy, Quintiles. “The ability to cut through all the noise and predict potential risks before they occur means we can target the right action at the right place at the right time. It is a major step forward in improving quality and productivity in the next generation of RBM execution.” 

Quintiles is currently engaged in more than 130 studies using RBM processes and policies, across more than 26,000 sites and 260,000 patients. Compliant with U.S. Food and Drug Association, European Medicines Agency and TransCelerate guidance, Predictive and Advanced Analytics use unique statistical algorithms specifically designed for optimal RBM execution. The capabilities combine inputs across multiple variables including operational performance and study data to provide unprecedented insights into potential study risks.

“Being able to target patients and sites with this level of accuracy takes RBM to a new level in terms of both speed and quality,” said Teresa Lamantia, senior vice president, knowledge management, Quintiles. “The ability to focus resources where they’re needed to protect patient safety and the integrity of the trial is a welcome advance for all of us working to transform clinical development.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research